CMS updates eligible hospital eCQM specs, unveils new tool

Updated specifications for the eligible hospital 2014 clinical quality measures (eCQMs) finalized in Meaningful Use Stage 2 of the EHR incentive program are now available on the Centers for Medicare & Medicaid Services (CMS) website. 

Also, a new tool called Bonnie was launched that supports measure developers in an e-specification of clinical quality measures, according to a blog post by Kevin Larsen, MD, medical director of Meaningful Use at ONC.

The updated specifications represent a collaborative effort between CMS, the Office of the National Coordinator for Health IT (ONC), the National Library of Medicine and the Agency for Healthcare Research and Quality.

“For Meaningful Use Stage 2, the certification of EHR technology is necessary to ensure the accurate capture, calculation and reporting of eCQMs and the electronic reporting of quality data to CMS. Data on these measures give invaluable feedback to providers on performance and clinician alignment with best practices,” wrote Larsen.

As for the new tool, Bonnie, it will allow developers to do the following:

  • Independently load quality measure definitions from the Measure Authoring Tool
  • Convert measure definitions into a format allowing execution of the measure logic
  • Rapidly craft synthetic test patients
  • Provide expected results for the test patients and evaluate if the defined logic behaves as expected, or deviates from the intent of the measure

“We look forward to full implementation of electronic reporting in 2014 and the certification of EHRs that use eCQMs. We welcome your feedback on the updated Meaningful Use Stage 2 eCQMs, resources provided, new testing tool and how we can continue to serve you better,” wrote Larsen.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.